This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nearly every hospital pharmacy across the U.S. And the problem has become so bad – especially for chemotherapies — that one-third of hospital pharmacists reported their institutions are rationing, delaying, or canceling treatments or procedures, according to a new survey.
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.
Dennis Killian, PharmD, PhD Vice President of Clinical Operations, TidalHealth Early on in my hospital pharmacy career, I had the pleasure of working with several tenured pharmacy leaders who were winding down their careers as staff pharmacists. One of these pharmacists had served as the CEO for a local hospital.
Pharmacists who work in inpatient hospital and infusion pharmacies have many responsibilities. Most of the time, I am working on review patient charts and find what interventions we can do to maximum efficacy of the patients' treatment plan to improve patient health conditions and reduce the time of hospital stay.
They identified a total of 28 genes in 12 strains of chemoresistant cell lines each against cisplatin, 5-fluorouracil, paclitaxel and docetaxel chemotherapies. Unfortunately, there are lots of people out there who do not respond to chemotherapy or radiation. In Europe, head and neck cancers affect around 22 people per 100,000.
The most common reasons ondansetron is needed in cats are chemotherapy, drug treatment, and pancreatitis (inflamed pancreas). Chemotherapy and drug-induced vomiting Like dogs and humans, cats can get malignant cancers that require chemotherapy. As in humans, doses may be given both before and after chemotherapy.
In human patients, it’s used to treat vomiting and nausea due to cancer chemotherapy or radiation therapy. Veterinarians commonly use ondansetron for chemotherapy, but its use in dogs is “ off-label.” Nausea-inducing chemotherapy is a common reason veterinarians give dogs ondansetron. Can dogs overdose on ondansetron?
Common drug classes that have been in short supply include: Antibiotics Electrolytes Hormone agents Chemotherapy Central nervous system drugs GLP-1 agonists What causes a medication shortage? However, if this isn’t an option, pharmacists may need to consider outsourcing to a compounding pharmacy.
Veterinarians may use it in a cat to prevent nausea and vomiting due to chemotherapy. Pet parents will use tablets made for humans or mirtazapine custom-made by a compounding pharmacy. If a dog is given too much mirtazapine, call an animal poison control center, talk to the veterinarian, or take the dog to a veterinary hospital.
Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.
Alpha 1 Globulins Alpha-1 globulins serve as transport proteins, which carry compounds to other tissues or organs in the body. Secondary hypogammaglobulinemia: In secondary hypogammaglobulinemia, low levels of immunoglobulin occur due to certain medical conditions or medicines, such as an immunosuppressant drug or chemotherapy.
1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.
Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.
Secondary outcomes included rates of specialist referrals and asthma-related emergency department (ED) visits or hospitalizations. Asthma exacerbations requiring acute care were rare but notable: 1 patient visited the ED, and 3 were hospitalized, all of whom were in the track 2 group.
Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. REFERENCES 1. Updated August 18, 2021.
For example, CPAs are especially impactful in managing chronic conditions such as diabetes, heart failure, and rheumatoid arthritis, where pharmacist intervention has been shown to improve outcomes and reduce hospitalizations. Subscribe Now!
The convenience of once-daily dosing and a rapid IV bolus administration may offer workflow efficiencies in hospital or surgical settings, where minimizing polypharmacy and streamlining medication administration are important goals.
Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.
Impact of a combined pharmacist and social worker program to reduce hospital readmissions. Pharmacy’s Appointment Based Model: medication synchronization align my refills. APhA Foundation. Accessed May 5, 2025. Gil M, Mikaitis DK, Shier G, Johnson TJ, Sims S. J Manag Care Pharm. 2013;19(7):558-563. doi:10.18553/jmcp.2013.19.7.558
Development Trends: Oncology at the Forefront Gene therapy currently ranks third among therapeutic focus areas, with 2151 compounds in development in 2024 ( Figure ). 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. 6 CAR T-cell therapies continue to dominate the genetically modified space.
They have a team of highly skilled distribution professionals who can juggle efficacy and safety checks along with compounding as if they were conductors of a world-class symphony. We need people to coordinate and track prior authorizations, write persuasive appeal letters, and keep patients updated.
Conclusions We demonstrated the feasibility of leveraging a complex EHR data source from an integrated health system to study the impact of dose modifications on clinical outcomes for self-administered chemotherapy. Nearly half of the patients with CML on imatinib experienced dosage modifications in this study.
This entails an increased risk of developing secondary diseases, such as type 2 diabetes and cardiovascular diseases,” Wile Balkhed, PhD student at Linköping University and resident physician at Linköping University Hospital, said in a news release.
Additionally, patients may have received prior chemotherapy for advanced disease. Additionally, taletrectinib was granted priority review, breakthrough designation, and orphan drug designation for this indication. For both trials, the major efficacy outcomes were confirmed overall response rate (cORR) and duration of response (DOR).
At Children’s Hospital of Philadelphia (CHOP), eligible patients can access 12 advanced therapeutics and 8 more in the pipeline. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. The infection risks are a little different.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Clinical Applications and Economic Impacts Biologics have significantly impacted cancer therapies by targeting cancer cells more specifically and reducing adverse events compared with traditional chemotherapy, Darkow noted.
Paula : I do, primarily I am a compounder, that is how I started out. I am manipulating something for an end product and that’s what I like about compounding - the end product, and [the process of] coming to it. I had been working at a pharmacy in Flint as a technician for about three years doing chemotherapycompounding.
whether growing or not; its seeds; resin extracted from any part; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin. chemotherapy-induced), pain, and post-traumatic stress disorder. chemotherapy-induced), and pain. chemotherapy-induced), and pain. 21 U.S.C. §
SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option. The CheckMate 816 trial showed a high pathological complete response rate without increased adverse events, supporting nivolumab as a standard treatment.
Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
The Trump administration wants to bring the production of more drugs, including medicines like antibiotics that may be in short supply, closer to the patient — including inside the hospital , Bloomberg News says. If successful, the new program, called Equip-A-Pharma, would bolster the U.S.
A recent study assessing the carbon footprint of a hospital pharmacys cytotoxic drug production unit and its main sources of greenhouse gas (GHG) emissions has revealed potential areas for improvement to reduce its global warming impact. Carbon footprint of a chemotherapy production unit within a hospital pharmacy: Time for green pharmacy.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content